Claude Nicaise is of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 18,174 shares of SRPT, which is worth approximately $2.19 Million. The most recent transaction as insider was on Mar 01, 2024, when has been sold 1,846 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.2K
0% 3M change
11.31% 12M change
Total Value Held $2.19 Million

Claude Nicaise Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2024
BUY
Grant, award, or other acquisition
-
1,846 Added 9.22%
18,174 Common Stock
Mar 06 2023
BUY
Grant, award, or other acquisition
-
1,523 Added 8.53%
16,328 Common Stock
Mar 07 2022
BUY
Grant, award, or other acquisition
-
2,953 Added 16.63%
14,805 Common Stock
Mar 03 2021
BUY
Grant, award, or other acquisition
-
2,726 Added 18.7%
11,852 Common Stock

Also insider at

CMMB
Chemomab Therapeutics Ltd. Healthcare
GANX
Gain Therapeutics, Inc. Healthcare
SAVA
CASSAVA SCIENCES INC Healthcare
CN

Claude Nicaise

Bethesda, MD

Track Institutional and Insider Activities on SRPT

Follow Sarepta Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT